Suppr超能文献

氚标记阿片类药物与阿片肽结合特性的比较。

Comparison of the binding characteristics of tritiated opiates and opioid peptides.

作者信息

Gillan M G, Kosterlitz H W, Paterson S J

出版信息

Br J Pharmacol. 1980 Nov;70(3):481-90. doi: 10.1111/j.1476-5381.1980.tb08727.x.

Abstract

1 Binding assays on homogenates of guinea-pig brain showed that the maximal number of binding sites was different tritiated ligands interacting with the opiate receptors. 2 At 25 degrees C the binding capacity of morphine or dihydromorphine was only about 3 pmol/g fresh brain whereas etorphine and D-Ala2-L-Leu5- and D-Ala2-L-Met5-enkephalin amide had capacities of 13 to 15 pmol/g brain. D-Ala2-D-Leu5-enkephalin had an intermediate capacity of about 6 pmol/g brain. 3 The binding capacities of the natural methionine- and leucine-enkephalins measured at 0 degrees C were 5 to 6 pmol/g brain. At this temperature, the binding capacity of dihydromorphine, D-Ala2-D-Leu5-enkephalin and of the two enkephalin amides was only slightly lower than at 25 degrees C. 4 In assays in which unlabelled ligand competed with the same labelled ligand, the inhibition constants (KI) were equal to or not more than twice as large as the equilibrium dissociation constant (KD) determined in saturation assays. In contrast, the KI of unlabelled dihydromorphine against [3H]-D-Ala2-D-Leu5-enkephalin or of unlabelled D-Ala2-D-Leu5-enkephalin against [3H]-dihydromorphine was about 20 times higher than the respective KD values. 5 When for a given compound the ratio of the KI value against [3H]-D-Ala2-D-Leu5-enkephalin to the KI value against [3H]-dihydromorphine (discrimination ratio) is calculated, a high value indicates selectivity in favour of the mu-receptor and a low value selectivity in favour of the delta-receptor. The most selective mu-agonist known so far is normorphine with a discrimination ratio of 70 and the most selective delta-agonist is D-Ala2-D-Leu5-enkephalin with a ratio of 0.11. The selectivity of the known antagonists is in favour of the mu-receptor, since their discrimination ratios are larger than 1, varying between 10 for naloxone and 4 for Mr 2266.

摘要
  1. 对豚鼠脑匀浆进行的结合试验表明,与阿片受体相互作用的不同氚标记配体的结合位点最大数量有所不同。2. 在25℃时,吗啡或二氢吗啡的结合能力仅约为3 pmol/g新鲜脑,而埃托啡以及D - Ala2 - L - Leu5 - 脑啡肽酰胺和D - Ala2 - L - Met5 - 脑啡肽酰胺的结合能力为13至15 pmol/g脑。D - Ala2 - D - Leu5 - 脑啡肽的结合能力约为6 pmol/g脑,处于中间水平。3. 在0℃测量的天然甲硫氨酸脑啡肽和亮氨酸脑啡肽的结合能力为5至6 pmol/g脑。在此温度下,二氢吗啡、D - Ala2 - D - Leu5 - 脑啡肽以及两种脑啡肽酰胺的结合能力仅略低于25℃时的水平。4. 在未标记配体与相同标记配体竞争的试验中,抑制常数(KI)等于或不超过饱和试验中测定的平衡解离常数(KD)的两倍。相比之下,未标记的二氢吗啡对[3H] - D - Ala2 - D - Leu5 - 脑啡肽或未标记的D - Ala2 - D - Leu5 - 脑啡肽对[3H] - 二氢吗啡的KI值比各自的KD值高约20倍。5. 当计算给定化合物对[3H] - D - Ala2 - D - Leu5 - 脑啡肽的KI值与对[3H] - 二氢吗啡的KI值之比(鉴别率)时,高值表明对μ受体有选择性,低值表明对δ受体有选择性。迄今为止已知的最具选择性的μ激动剂是去甲吗啡,鉴别率为70,最具选择性的δ激动剂是D - Ala2 - D - Leu5 - 脑啡肽,鉴别率为0.11。已知拮抗剂的选择性有利于μ受体,因为它们的鉴别率大于1,纳洛酮的鉴别率为10,Mr 2266的鉴别率为至4。

相似文献

1
氚标记阿片类药物与阿片肽结合特性的比较。
Br J Pharmacol. 1980 Nov;70(3):481-90. doi: 10.1111/j.1476-5381.1980.tb08727.x.
2
中枢神经系统中多种吗啡和脑啡肽结合位点的分类
Proc Natl Acad Sci U S A. 1981 Oct;78(10):6181-5. doi: 10.1073/pnas.78.10.6181.
5
豚鼠脑中阿片受体κ亚型的特性研究
Br J Pharmacol. 1981 Aug;73(4):939-49. doi: 10.1111/j.1476-5381.1981.tb08749.x.
6
对D-丙氨酸2-D-亮氨酸5-脑啡肽(δ受体)和二氢吗啡(μ受体)结合位点的特异性保护。
Proc R Soc Lond B Biol Sci. 1979 Aug 31;205(1160):425-32. doi: 10.1098/rspb.1979.0076.
7
钙增强δ-而非μ-阿片受体激动剂结合。
Naunyn Schmiedebergs Arch Pharmacol. 1982 May;319(2):147-53. doi: 10.1007/BF00503929.
8
在豚鼠腰骶脊髓中使用阿片肽证明存在多个“κ”结合位点。
Neuropeptides. 1982 Oct;3(1):53-64. doi: 10.1016/0143-4179(82)90065-8.
10
阿片肽3H-甲硫氨酸脑啡肽的阿片受体结合相互作用。
Eur J Pharmacol. 1978 Feb 1;47(3):319-31. doi: 10.1016/0014-2999(78)90240-6.

引用本文的文献

1
下丘脑的阿片类物质控制伏隔核中的多巴胺和乙酰胆碱水平。
Brain Res. 2010 Feb 2;1312:1-9. doi: 10.1016/j.brainres.2009.11.055. Epub 2009 Nov 27.
2
壁报交流
Br J Pharmacol. 1993 Jul;109(Suppl):67P-142P.
3
克隆的青蛙和人类μ阿片受体的药理学比较揭示了阿片类药物亲和力和功能的差异。
Eur J Pharmacol. 2008 Dec 3;599(1-3):36-43. doi: 10.1016/j.ejphar.2008.09.043. Epub 2008 Oct 9.
4
选择性阿片类激动剂和拮抗剂在两栖动物脊髓中对[3H]-纳洛酮结合的竞争。
Brain Res. 2000 Nov 24;884(1--2):184-91. doi: 10.1016/s0006-8993(00)02967-x.
5
利培酮与新型及参比抗精神病药物的比较:体外和体内受体结合情况
Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73. doi: 10.1007/BF02245606.
6
牛脑和肺的粗甲醇提取物中存在一种非儿茶酚胺类、可置换可乐定的物质的证据。
Naunyn Schmiedebergs Arch Pharmacol. 1995 Jan;351(1):17-26. doi: 10.1007/BF00169059.
7
纳洛酮对阿片类药物诱导的脑片乙酰胆碱释放抑制和促进作用的影响。
Br J Pharmacol. 1982 Jul;76(3):393-401. doi: 10.1111/j.1476-5381.1982.tb09233.x.
9
双青霉胺脑啡肽对δ阿片受体具有高度改善的特异性。
Proc Natl Acad Sci U S A. 1983 Oct;80(19):5871-4. doi: 10.1073/pnas.80.19.5871.
10
具有“κ”配体选择性模式的大鼠脑阿片受体的可视化与增溶作用。
Cell Mol Neurobiol. 1982 Dec;2(4):333-46. doi: 10.1007/BF00710853.

本文引用的文献

1
脑啡肽结构变化及麻醉性镇痛药对其与μ和δ受体相互作用的影响。
Br J Pharmacol. 1980 Feb;68(2):333-42. doi: 10.1111/j.1476-5381.1980.tb10422.x.
2
阿片类麻醉药在3H-二氢吗啡与大鼠脑膜结合中的立体特异性相互作用。
Life Sci. 1973 Dec 1;13(11):1543-56. doi: 10.1016/0024-3205(73)90143-4.
3
强效麻醉性镇痛药(3H)埃托啡与大鼠脑匀浆的立体特异性结合。
Proc Natl Acad Sci U S A. 1973 Jul;70(7):1947-9. doi: 10.1073/pnas.70.7.1947.
4
抑制常数(K1)与导致酶促反应50%抑制率(I50)的抑制剂浓度之间的关系。
Biochem Pharmacol. 1973 Dec 1;22(23):3099-108. doi: 10.1016/0006-2952(73)90196-2.
5
大鼠脑中新型高亲和力阿片受体结合的鉴定。
Nature. 1975 Feb 13;253(5492):563-5. doi: 10.1038/253563a0.
8
亮氨酸脑啡肽和甲硫氨酸脑啡肽与大鼠大脑微粒体部分的结合。
FEBS Lett. 1977 May 15;77(2):209-13. doi: 10.1016/0014-5793(77)80236-6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验